In another study, Teunissen et al. (2011) found a rise in B-FABP levels in the serum of individuals with Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurological disorders related to dementia compared to non-dementia patients, indicating that B-FABP has potential as a biomarker for these neurodegenerative diseases. This evidence concerns the gene FABP7 and Parkinson disease.